{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:28:15Z","timestamp":1789424895307,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022CZR88M"],"award-info":[{"award-number":["PRIN 2022CZR88M"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P20227KXJK"],"award-info":[{"award-number":["P20227KXJK"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02221-1","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:01:52Z","timestamp":1698296512000},"page":"1101-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-0530","authenticated-orcid":false,"given":"E.","family":"Vitali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Panzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Uccella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"2221_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182\u2013188. https:\/\/doi.org\/10.1111\/his.13975","journal-title":"Histopathology"},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185","journal-title":"Neuroendocrinology"},{"key":"2221_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28:245\u2013255. https:\/\/doi.org\/10.1200\/JCO.2008.21.5988","journal-title":"J Clin Oncol"},{"key":"2221_CR5","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.5754\/hge11212","volume":"58","author":"CF Zhou","year":"2011","unstructured":"Zhou CF, Ji J, Yuan F et al (2011) mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepatogastroenterology 58:2140\u20132143. https:\/\/doi.org\/10.5754\/hge11212","journal-title":"Hepatogastroenterology"},{"key":"2221_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors for the RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group. N Engl J Med 364:514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"key":"2221_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JJC Yao","year":"2016","unstructured":"Yao JJC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968\u2013977. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X","journal-title":"Lancet"},{"key":"2221_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.2016.25","volume":"114","author":"T Vandamme","year":"2016","unstructured":"Vandamme T, Beyens M, De Beeck KO et al (2016) Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. Br J Cancer 114:650\u2013658. https:\/\/doi.org\/10.1038\/bjc.2016.25","journal-title":"Br J Cancer"},{"key":"2221_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000362339","volume":"99","author":"MC Berkovic","year":"2014","unstructured":"Berkovic MC, Cacev T, Ivkovic TC et al (2014) New insights into the role of chronic inflammation and cytokines in the etiopathogenesis of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 99:75\u201384. https:\/\/doi.org\/10.1159\/000362339","journal-title":"Neuroendocrinology"},{"key":"2221_CR10","doi-asserted-by":"publisher","first-page":"102840","DOI":"10.1016\/j.critrevonc.2019.102840","volume":"146","author":"G Vitale","year":"2020","unstructured":"Vitale G, Carra S, Ferra\u00f9 F et al (2020) Gastroenteropancreatic neuroendocrine neoplasms and inflammation: a complex cross-talk with relevant clinical implications. Crit Rev Oncol Hematol 146:102840","journal-title":"Crit Rev Oncol Hematol"},{"key":"2221_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11154-020-09589-y","volume":"22","author":"G Vitale","year":"2021","unstructured":"Vitale G, Dicitore A, Barrea L et al (2021) From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: are we on the highway to hell? Rev Endocr Metab Disord 22:511\u2013525. https:\/\/doi.org\/10.1007\/s11154-020-09589-y","journal-title":"Rev Endocr Metab Disord"},{"key":"2221_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejphar.2017.02.034","volume":"802","author":"M Temiz-resitoglu","year":"2017","unstructured":"Temiz-resitoglu M, Sinem D, Cecen P (2017) Activation of mTOR\/I\u03baB-\u03b1\/NF-\u03baB pathway contributes to LPS-induced hypotension and inflammation in rats. Eur J Pharmacol 802:7\u201319. https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.034","journal-title":"Eur J Pharmacol"},{"key":"2221_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4049\/jimmunol.153.1.153","volume":"153","author":"C Kunsch","year":"1994","unstructured":"Kunsch C, Lang RK, Rosen CA, Shannon MF (1994) Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J Immunol 153:153\u2013164. https:\/\/doi.org\/10.4049\/jimmunol.153.1.153","journal-title":"J Immunol"},{"key":"2221_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cyto.2009.11.010","volume":"49","author":"F Hussain","year":"2010","unstructured":"Hussain F, Wang J, Ahmed R et al (2010) Cytokine The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 49:134\u2013140. https:\/\/doi.org\/10.1016\/j.cyto.2009.11.010","journal-title":"Cytokine"},{"key":"2221_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-05-0231","author":"SJ Braeuer","year":"2006","unstructured":"Braeuer SJ, B\u00fcneker C, Mohr A, Zwacka RM (2006) Constitutively activated nuclear factor-\u03baB, but not induced NF-\u03baB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-05-0231","journal-title":"Mol Cancer Res"},{"key":"2221_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M (2018) REVIEWS NF-\u03baB, inflammation, immunity and cancer\u202f: coming of age. Nat Publ Gr 18:309\u2013324. https:\/\/doi.org\/10.1038\/nri.2017.142","journal-title":"Nat Publ Gr"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11605-019-04261-6","volume":"24","author":"AG Lopez-aguiar","year":"2019","unstructured":"Lopez-aguiar AG, Postlewait LM, Ethun CG et al (2019) STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors\u202f: potential for a new therapeutic target? J Gastrointest Surg 24:1138\u20131148","journal-title":"J Gastrointest Surg"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/S0092-8674(02)00703-1","volume":"109","author":"S Ghosh","year":"2002","unstructured":"Ghosh S, Karin M (2002) Missing pieces in the NF-\u03baB puzzle. Cell 109:S81\u2013S96","journal-title":"Cell"},{"key":"2221_CR19","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","volume":"25","author":"DS Bass\u00e8res","year":"2006","unstructured":"Bass\u00e8res DS, Baldwin AS (2006) Nuclear factor-\u03baB and inhibitor of \u03baB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817\u20136830","journal-title":"Oncogene"},{"key":"2221_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/0-306-48158-8_10","volume":"115","author":"TD Gilmore","year":"2003","unstructured":"Gilmore TD (2003) The Re1\/NF-kappa B\/I kappa B signal transduction pathway and cancer. Cancer Treat Res 115:241\u2013265","journal-title":"Cancer Treat Res"},{"key":"2221_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11\u201319. https:\/\/doi.org\/10.1016\/j.cytogfr.2009.11.005","journal-title":"Cytokine Growth Factor Rev"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/ni1012","volume":"4","author":"M Kubo","year":"2003","unstructured":"Kubo M, Hanada T, Yoshimura A (2003) Suppressors of cytokine signaling and immunity. Nat Immunol 4:1169\u20131176","journal-title":"Nat Immunol"},{"key":"2221_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) Stat3 as an oncogene. Cell 98:295\u2013303. https:\/\/doi.org\/10.1016\/S0092-8674(00)81959-5","journal-title":"Cell"},{"key":"2221_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R (2004) The stats of cancer\u2014new molecular targets come of age. Nat Rev Cancer 4:97\u2013105","journal-title":"Nat Rev Cancer"},{"key":"2221_CR25","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1172\/JCI32533","volume":"117","author":"P Sansone","year":"2007","unstructured":"Sansone P, Storci G, Tavolari S et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988\u20134002. https:\/\/doi.org\/10.1172\/JCI32533","journal-title":"J Clin Invest"},{"key":"2221_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-4598-5-15","volume":"6","author":"YZ Yin","year":"2006","unstructured":"Yin YZ, Wang YC (2006) Analysis of behaviour of steel beams with web openings at elevated temperatures. Steel Compos Struct 6:15\u201331. https:\/\/doi.org\/10.1186\/1476-4598-5-15","journal-title":"Steel Compos Struct"},{"key":"2221_CR27","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1038\/onc.2012.546","volume":"32","author":"D Kesanakurti","year":"2013","unstructured":"Kesanakurti D, Chetty C, Rajasekhar Maddirela D et al (2013) Essential role of cooperative NF-\u03baB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene 32:5144\u20135155. https:\/\/doi.org\/10.1038\/onc.2012.546","journal-title":"Oncogene"},{"key":"2221_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J (2013) NF- \u03ba B and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4:176\u2013185. https:\/\/doi.org\/10.1007\/s13238-013-2084-3","journal-title":"Protein Cell"},{"key":"2221_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.110803","volume":"509","author":"E Vitali","year":"2020","unstructured":"Vitali E, Boemi I, Piccini S et al (2020) A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells. Mol Cell Endocrinol 509:110803. https:\/\/doi.org\/10.1016\/j.mce.2020.110803","journal-title":"Mol Cell Endocrinol"},{"key":"2221_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/ERC-15-0358","volume":"23","author":"E Vitali","year":"2016","unstructured":"Vitali E, Cambiaghi V, Zerbi A et al (2016) Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer 23:181\u2013190. https:\/\/doi.org\/10.1530\/ERC-15-0358","journal-title":"Endocr Relat Cancer"},{"key":"2221_CR31","doi-asserted-by":"publisher","first-page":"77330","DOI":"10.18632\/oncotarget.20473","volume":"8","author":"E Vitali","year":"2017","unstructured":"Vitali E, Boemi I, Rosso L et al (2017) FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget 8:77330\u201377340. https:\/\/doi.org\/10.18632\/oncotarget.20473","journal-title":"Oncotarget"},{"key":"2221_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082143","volume":"12","author":"E Vitali","year":"2020","unstructured":"Vitali E, Boemi I, Tarantola G et al (2020) Metformin and everolimus: a promising combination for neuroendocrine tumors treatment. Cancers (Basel) 12:1\u201318. https:\/\/doi.org\/10.3390\/cancers12082143","journal-title":"Cancers (Basel)"},{"key":"2221_CR33","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1158\/0008-5472.CAN-04-1847","volume":"64","author":"AG Lania","year":"2004","unstructured":"Lania AG, Mantovani G, Ferrero S et al (2004) Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase A regulatory subunit 1A protein. Cancer Res 64:9193\u20139198. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1847","journal-title":"Cancer Res"},{"key":"2221_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1530\/ERC-19-0086","volume":"26","author":"AD Herrera-Mart\u00ednez","year":"2019","unstructured":"Herrera-Mart\u00ednez AD, van den Dungen R, Dogan-Oruc F et al (2019) Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocr Relat Cancer 26:585\u2013599. https:\/\/doi.org\/10.1530\/ERC-19-0086","journal-title":"Endocr Relat Cancer"},{"key":"2221_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.hoc.2015.09.005","volume":"30","author":"N Raj","year":"2016","unstructured":"Raj N, Reidy-Lagunes D (2016) Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am 30:119\u2013133","journal-title":"Hematol Oncol Clin North Am"},{"key":"2221_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","volume":"19","author":"L Lee","year":"2018","unstructured":"Lee L, Ito T, Jensen RT (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19:909\u2013928. https:\/\/doi.org\/10.1080\/14656566.2018.1476492","journal-title":"Expert Opin Pharmacother"},{"key":"2221_CR37","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500\u20131508. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2925","journal-title":"Cancer Res"},{"key":"2221_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.17305\/bjbms.2020.4471","volume":"20","author":"DH Mahe\u010di\u0107","year":"2020","unstructured":"Mahe\u010di\u0107 DH, Berkovi\u0107 MC, Zja\u010di\u0107-Rotkvi\u0107 V et al (2020) Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms. Bosn J Basic Med Sci 20:445\u2013450. https:\/\/doi.org\/10.17305\/bjbms.2020.4471","journal-title":"Bosn J Basic Med Sci"},{"key":"2221_CR39","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJJ Waugh","year":"2008","unstructured":"Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735\u20136741","journal-title":"Clin Cancer Res"},{"key":"2221_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/molehr\/7.8.787","volume":"7","author":"CL Elliott","year":"2001","unstructured":"Elliott CL, Allport VC, Loudon JAZ et al (2001) Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod 7:787\u2013790. https:\/\/doi.org\/10.1093\/molehr\/7.8.787","journal-title":"Mol Hum Reprod"},{"key":"2221_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M (2018) NF-B, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18:309\u2013324","journal-title":"Nat Rev Immunol"},{"key":"2221_CR42","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/ijc.24748","volume":"125","author":"D Bai","year":"2009","unstructured":"Bai D, Ueno L, Vogt PK (2009) Akt-mediated regulation of NF\u03baB and the essentialness of NF\u03baB for the oncogenicity of PI3K and Akt. Int J Cancer 125:2863\u20132870. https:\/\/doi.org\/10.1002\/ijc.24748","journal-title":"Int J Cancer"},{"key":"2221_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/PAI.0000000000000359","volume":"25","author":"SM El Jamal","year":"2017","unstructured":"El Jamal SM, Yaseen AA, Alatassi H et al (2017) Strong NFkB expression is associated with high-grade dysplasia in Barrett\u2019s esophagus. Appl Immunohistochem Mol Morphol 25:329\u2013333. https:\/\/doi.org\/10.1097\/PAI.0000000000000359","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2221_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13193-013-0234-y","volume":"4","author":"DK Sarkar","year":"2013","unstructured":"Sarkar DK, Jana D, Patil PS et al (2013) Role of NF-\u03baB as a prognostic marker in breast cancer: a pilot study in Indian patients. Indian J Surg Oncol 4:242\u2013247. https:\/\/doi.org\/10.1007\/s13193-013-0234-y","journal-title":"Indian J Surg Oncol"},{"key":"2221_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25190","author":"CM Annunziata","year":"2010","unstructured":"Annunziata CM, Stavnes HT, Kleinberg L et al (2010) Nuclear factor \u03baB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. https:\/\/doi.org\/10.1002\/cncr.25190","journal-title":"Cancer"},{"key":"2221_CR46","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1535-7163.MCT-17-0786","volume":"17","author":"S Inoue","year":"2018","unstructured":"Inoue S, Ide H, Mizushima T et al (2018) Nuclear factor-kb promotes urothelial tumorigenesis and cancer progression via cooperation with androgen receptor signaling. Mol Cancer Ther 17:1303\u20131314. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0786","journal-title":"Mol Cancer Ther"},{"key":"2221_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11091502","volume":"14","author":"HA Bakshi","year":"2022","unstructured":"Bakshi HA, Quinn GA, Nasef MM et al (2022) Crocin inhibits angiogenesis and metastasis in colon cancer via TNF-\u03b1\/NF-kB\/VEGF pathways. Cells 14:1\u201315. https:\/\/doi.org\/10.3390\/cells11091502","journal-title":"Cells"},{"key":"2221_CR48","doi-asserted-by":"publisher","unstructured":"Transl S, Author M, August PMC, et al (2022) CECR2 drives breast cancer metastasis by promoting NF-\u03baB signaling and macrophage-mediated immune suppression HHS public access. 14:1\u201333. https:\/\/doi.org\/10.5281\/zenodo.5797228","DOI":"10.5281\/zenodo.5797228"},{"key":"2221_CR49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J (2013) NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4:176\u2013185","journal-title":"Protein Cell"},{"key":"2221_CR50","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/sj.onc.1208442","volume":"24","author":"M Burger","year":"2005","unstructured":"Burger M, Hartmann T, Burger JA, Schraufstatter I (2005) KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 24:2067\u20132075. https:\/\/doi.org\/10.1038\/sj.onc.1208442","journal-title":"Oncogene"},{"key":"2221_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078728","author":"BC Mcfarland","year":"2013","unstructured":"Mcfarland BC, Hong SW, Rajbhandari R et al (2013) NF-\u03baB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0078728","journal-title":"PLoS ONE"},{"key":"2221_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01626-z","author":"H Chen","year":"2021","unstructured":"Chen H, Bian A, Yang FL et al (2021) Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Oncogene. https:\/\/doi.org\/10.1038\/s41388-020-01626-z","journal-title":"Oncogene"},{"key":"2221_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309\u2013324. https:\/\/doi.org\/10.1038\/nprot.2008.226","journal-title":"Nat Protoc"},{"key":"2221_CR54","doi-asserted-by":"publisher","first-page":"R369","DOI":"10.1530\/ERC-19-0087","volume":"26","author":"P Khongthong","year":"2019","unstructured":"Khongthong P, Roseweir AK, Edwards J (2019) The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocr Relat Cancer 26:R369\u2013R380. https:\/\/doi.org\/10.1530\/ERC-19-0087","journal-title":"Endocr Relat Cancer"},{"key":"2221_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01047","author":"C Sciammarella","year":"2020","unstructured":"Sciammarella C, Luce A, Riccardi F et al (2020) Lanreotide induces cytokine modulation in intestinal neuroendocrine tumors and overcomes resistance to everolimus. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.01047","journal-title":"Front Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02221-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:20:14Z","timestamp":1713770414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02221-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02221-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This research was performed in accordance with the ethical standards of the\u00a0Independent Ethics Committee of Istituto Clinico Humanitas\u2014IRCCS, Rozzano (Milan)\u00a0and with the 1964 Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}